

BCCA Protocol Summary for ADRIAMYCIN® and DTIC Program for use in Patients with Soft Tissue Sarcoma

Protocol Code: SAAVADIC
Tumour Group: Sarcoma
Contact Physician: Dr Meg Knowling

ELIGIBILITY/TESTS:

Patient with advanced incurable soft tissue sarcoma
Path not rhabdomyosarcoma, Ewings sarcoma or peripheral neuroectodermal tumor
Normal cardiac and hepatic function
PRE-Rx: CBC, LFTs, bilirubin, weight, ECOG-PS.

PREMEDICATIONS:

Antiemetic protocol for highly emetogenic chemotherapy (see protocol SCNAUSEA)

TREATMENT:

1. Doxorubicin 60 mg/m² IV. (ADRIAMYCIN® may be escalated by 10 mg/m² if treatment day granulocyte count greater than 2500 and no interval complications).
2. Dacarbazine 850 mg/m² IV q 3 weekly x 6

DOSE MODIFICATIONS:

1. **Hematologic Toxicity:** Treatment day counts (modify both drugs)

ANC*	greater than or equal to 1.5	and	platelets	greater than or equal to 100	100%
ANC	1.0-1.49	or	platelets	70-99	80%
ANC	less than 1.0	or	platelets	less than 70	delay 1/52

* Absolute neutrophil count

2. **Mucositis** Grade 3 or 4 reduce doxorubicin by 20%.
3. **Neutropenic Fever** with ANC less than 500 reduce both drugs by 20%.
CXR every third treatment. Whole lung tomography before Rx and at completion. Baseline EKG with treatment number 1 or 2.

Call Dr. Meg Knowling or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: N/A

Date revised: 1 Jun 2010 (Premedications revised)